Walleye Capital LLC Apellis Pharmaceuticals, Inc. Call Options Transaction History

Walleye Capital LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$38.07 - $59.71 $1.64 Million - $2.57 Million	-43,100 Reduced 77.1%	12,800 $491,000
Q1 2024 May 15, 2024	BUY	$55.39 - $72.47 $2.54 Million - $3.33 Million	45,900 Added 459.0%	55,900 $3.29 Million
Q4 2023 Feb 14, 2024	SELL	$37.14 - $64.82 $1.14 Million - $1.99 Million	-30,700 Reduced 75.43%	10,000 $598,000
Q3 2023 Nov 14, 2023	BUY	$23.65 - $89.22 $643,280 - $2.43 Million	27,200 Added 201.48%	40,700 $1.55 Million
Q2 2023 Aug 14, 2023	BUY	$76.68 - $93.31 $567,432 - $690,494	7,400 Added 121.31%	13,500 $1.23 Million
Q1 2023 May 15, 2023	SELL	$46.59 - $66.96 $568,398 - $816,911	-12,200 Reduced 66.67%	6,100 $402,000
Q4 2022 Feb 14, 2023	BUY	$43.24 - $61.04 $155,664 - $219,744	3,600 Added 24.49%	18,300 $946,000
Q3 2022 Nov 14, 2022	BUY	$44.76 - $69.66 $657,972 - $1.02 Million	14,700 New	14,700 $1 Million
Q2 2020 Aug 14, 2020	SELL	$24.8 - $38.49 $235,600 - $365,655	-9,500 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$17.91 - $44.33 $170,145 - $421,135	9,500 New	9,500 $255,000

308

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.